Skip to Content

Generic Stalevo 125 Availability

Last updated on Sep 8, 2021.

See also: Generic Stalevo 100, Generic Stalevo 150, Generic Stalevo 200, Generic Stalevo 50, Generic Stalevo 75

Stalevo 125 is a brand name of carbidopa/entacapone/levodopa, approved by the FDA in the following formulation(s):

STALEVO 125 (carbidopa; entacapone; levodopa - tablet;oral)

  • Manufacturer: ORION PHARMA
    Approval date: August 29, 2008
    Strength(s): 31.25MG;200MG;125MG [RLD]

Has a generic version of Stalevo 125 been approved?

An Authorized Generic version of Stalevo 125 has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.

List of authorized generic versions:

  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 25; 100; 200 mg/1; mg/1; mg
    Mylan Pharmaceuticals Inc.
    NDC Code: 003788302
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 31.25; 125; 200 mg/1; mg/1; mg
    Mylan Pharmaceuticals Inc.
    NDC Code: 003788303
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 50; 200; 200 mg/1; mg/1; mg
    Mylan Pharmaceuticals Inc.
    NDC Code: 003788305
  • Carbidopa, Levodopa, and Entacapone ORAL TABLET, FILM COATED 12.5; 50; 200 mg/1; mg/1; mg
    Sandoz Inc
    NDC Code: 007815613
  • Carbidopa, Levodopa, and Entacapone ORAL TABLET, FILM COATED 18.75; 75; 200 mg/1; mg/1; mg
    Sandoz Inc
    NDC Code: 007815625
  • Carbidopa, Levodopa, and Entacapone ORAL TABLET, FILM COATED 25; 100; 200 mg/1; mg/1; mg
    Sandoz Inc
    NDC Code: 007815637
  • Carbidopa, Levodopa, and Entacapone ORAL TABLET, FILM COATED 31.25; 125; 200 mg/1; mg/1; mg
    Sandoz Inc
    NDC Code: 007815641
  • Carbidopa, Levodopa, and Entacapone ORAL TABLET, FILM COATED 37.5; 150; 200 mg/1; mg/1; mg
    Sandoz Inc
    NDC Code: 007815654
  • Carbidopa, Levodopa, and Entacapone ORAL TABLET, FILM COATED 50; 200; 200 mg/1; mg/1; mg
    Sandoz Inc
    NDC Code: 007815669
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 50; 200; 12.5 mg/1; mg/1; mg
    Wockhardt USA LLC.
    NDC Code: 646790782
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 75; 200; 18.75 mg/1; mg/1; mg
    Wockhardt USA LLC.
    NDC Code: 646790783
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 100; 200; 25 mg/1; mg/1; mg
    Wockhardt USA LLC.
    NDC Code: 646790784
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 125; 200; 31.25 mg/1; mg/1; mg
    Wockhardt USA LLC.
    NDC Code: 646790785
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 150; 200; 37.5 mg/1; mg/1; mg
    Wockhardt USA LLC.
    NDC Code: 646790786
  • carbidopa, levodopa and entacapone ORAL TABLET, FILM COATED 200; 200; 50 mg/1; mg/1; mg
    Wockhardt USA LLC.
    NDC Code: 646790787

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Stalevo 125. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.